- Home
- ULY vs GOVX Comparison
ULY vs GOVX Comparison
Compare ULY & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- GOVX
- Stock Information
- Founded
- ULY 2013
- GOVX 2001
- Country
- ULY United States
- GOVX United States
- Employees
- ULY N/A
- GOVX N/A
- Industry
- ULY
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ULY
- GOVX Health Care
- Exchange
- ULY Nasdaq
- GOVX Nasdaq
- Market Cap
- ULY 7.4M
- GOVX 7.6M
- IPO Year
- ULY N/A
- GOVX N/A
- Fundamental
- Price
- ULY $7.54
- GOVX $0.69
- Analyst Decision
- ULY Strong Buy
- GOVX Strong Buy
- Analyst Count
- ULY 2
- GOVX 5
- Target Price
- ULY $13.50
- GOVX $12.40
- AVG Volume (30 Days)
- ULY 1.3M
- GOVX 3.3M
- Earning Date
- ULY 08-11-2025
- GOVX 08-05-2025
- Dividend Yield
- ULY N/A
- GOVX N/A
- EPS Growth
- ULY N/A
- GOVX N/A
- EPS
- ULY N/A
- GOVX N/A
- Revenue
- ULY $134,085,000.00
- GOVX $5,591,576.00
- Revenue This Year
- ULY N/A
- GOVX N/A
- Revenue Next Year
- ULY $23.08
- GOVX N/A
- P/E Ratio
- ULY N/A
- GOVX N/A
- Revenue Growth
- ULY N/A
- GOVX N/A
- 52 Week Low
- ULY $2.99
- GOVX $0.43
- 52 Week High
- ULY $21.24
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- ULY 55.36
- GOVX 42.50
- Support Level
- ULY $6.57
- GOVX $0.60
- Resistance Level
- ULY $9.98
- GOVX $0.77
- Average True Range (ATR)
- ULY 1.19
- GOVX 0.09
- MACD
- ULY 0.30
- GOVX -0.01
- Stochastic Oscillator
- ULY 59.20
- GOVX 47.27
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.